Title:
FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY
Document Type and Number:
WIPO Patent Application WO/2018/113624
Kind Code:
A1
Abstract:
The invention discloses a type of fused imidazole compound, preparation method and application thereof. The structure of the compound is shown in general formula I. The definition of each group therein is as described in the specification. These compounds are capable of selectively inhibiting indoleamine 2,3-dioxygenase (IDO). The compounds can act as an IDO inhibitor for treating and/or preventing a disease having a pathological feature with IDO-mediated tryptophan metabolic pathways, for example, cancer, eye disease, autoimmune disease, psychological disorder, depression symptom, anxiety disorder and other diseases.
More Like This:
Inventors:
YU JINDI (CN)
LU XIANPING (CN)
LI ZHIBIN (CN)
XIN LIJUN (CN)
ZHU JIANGFEI (CN)
FU CHAO (CN)
LU XIANPING (CN)
LI ZHIBIN (CN)
XIN LIJUN (CN)
ZHU JIANGFEI (CN)
FU CHAO (CN)
Application Number:
PCT/CN2017/116914
Publication Date:
June 28, 2018
Filing Date:
December 18, 2017
Export Citation:
Assignee:
SHENZHEN CHIPSCREEN BIOSCIENCES LTD (CN)
International Classes:
C07D487/04; A61K31/4188; A61P37/02
Domestic Patent References:
| WO2016037026A1 | 2016-03-10 |
Foreign References:
| CN103547579A | 2014-01-29 | |||
| CN105189466A | 2015-12-23 | |||
| CN201611186194A | 2016-12-20 | |||
| CN1795187A | 2006-06-28 | |||
| CN101932325A | 2010-12-29 | |||
| CN103054870A | 2013-04-24 | |||
| CN101932325A | 2010-12-29 | |||
| CN102579452A | 2012-07-18 |
Other References:
LEKLEM J. E., AM J CLIN NUTR, vol. 24, no. 6, 1971, pages 659 - 672
YAMAOTO S. ET AL., J BIOL CHEM, vol. 242, no. 22, 1967, pages 5260 - 5266
MACKENZIE, C. R. ET AL., CURRENT DRUG METABOLISM, vol. 8, 2007, pages 237 - 244
FUSAO HIRATA ET AL., J BIOL CHEM, vol. 252, no. 13, 1977, pages 4637 - 4642
KING N. J. ET AL., THE INT J BIOCHEM CELL BIOL, vol. 39, no. 12, 2007, pages 2167 - 2172
MUNN D. H. ET AL., J EXP MED, vol. 189, no. 9, 1999, pages 1363 - 1372
MUNN D. H. ET AL., SCIENCE, vol. 281, no. 5380, 1998, pages 1191 - 1193
FRIBERG M. ET AL., INT J CANCER, vol. 101, no. 2, 2002, pages 151 - 155
TEMESS P. ET AL., BLOOD, vol. 105, no. 6, 2005, pages 2480 - 2486
ROY E. J. ET AL., NEUROSCI LETT, vol. 387, no. 2, 2005, pages 95 - 99
TAKIKAWA ET AL., ADV. EXP. MED. BIOL., vol. 467, 1999, pages 241 - 245
TAKIKAWA O. ET AL., EXP. EYE RES., vol. 72, 2001, pages 271 - 277
See also references of EP 3560928A4
YAMAOTO S. ET AL., J BIOL CHEM, vol. 242, no. 22, 1967, pages 5260 - 5266
MACKENZIE, C. R. ET AL., CURRENT DRUG METABOLISM, vol. 8, 2007, pages 237 - 244
FUSAO HIRATA ET AL., J BIOL CHEM, vol. 252, no. 13, 1977, pages 4637 - 4642
KING N. J. ET AL., THE INT J BIOCHEM CELL BIOL, vol. 39, no. 12, 2007, pages 2167 - 2172
MUNN D. H. ET AL., J EXP MED, vol. 189, no. 9, 1999, pages 1363 - 1372
MUNN D. H. ET AL., SCIENCE, vol. 281, no. 5380, 1998, pages 1191 - 1193
FRIBERG M. ET AL., INT J CANCER, vol. 101, no. 2, 2002, pages 151 - 155
TEMESS P. ET AL., BLOOD, vol. 105, no. 6, 2005, pages 2480 - 2486
ROY E. J. ET AL., NEUROSCI LETT, vol. 387, no. 2, 2005, pages 95 - 99
TAKIKAWA ET AL., ADV. EXP. MED. BIOL., vol. 467, 1999, pages 241 - 245
TAKIKAWA O. ET AL., EXP. EYE RES., vol. 72, 2001, pages 271 - 277
See also references of EP 3560928A4
Attorney, Agent or Firm:
SHENPAT INTELLECTUAL PROPERTY AGENCY (CN)
Download PDF: